Side effects of perioperative intravesical treatment and treatment strategies for these side effects (Q86507878)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Side effects of perioperative intravesical treatment and treatment strategies for these side effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Joshua G Griffin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jeff Holzbeierlein

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

19 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

Urologic Clinics of North America

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

197-210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Absorption of anticancer drugs through bladder epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Intravesical chemotherapy of superficial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Mitomycin C: a clinical update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

The significance of extravasation in oncological care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Extravasation of Chemotherapeutic Agents: Prevention and Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Cardiac, renal, and pulmonary toxicity of several mitomycin derivatives in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Vascular toxicity associated with antineoplastic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

[Pulmonary fibrosis and endovesical mitomycin C]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Pulmonary toxicity of antineoplastic agents: Anaesthetic and postoperative implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Mitomycin-induced pulmonary toxicity: case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Renal toxicity in man treated with mitomycin C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Renal toxicity of mitomycin-C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Renal complications of mitomycin C therapy with special reference to the total dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Mitomycin C-induced renal toxicity, a dose-dependent side effect?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Thiotepa in the treatment of tumours of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Cellular pharmacology of gemcitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Perivesical fat necrosis after adjuvant intravesical chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

[Bladder necrosis after an immediate post-operative mitomycin C instillation]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Perivesical inflammation after early mitomycin C instillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Unusual complication after immediate postoperative intravesical mitomycin C instillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

The actual incidence of bladder perforation following transurethral bladder surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Type III and type IV hypersensitivity reactions due to mitomycin C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Intravesical mitomycin C for superficial transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Benign ulcers after bladder instillation of mitomycin C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.005

10.1016/J.UCL.2013.01.005

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23540778%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference